Holen Sie sich die Stockscreener-App
440.11
0.42%
-1.93
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt VRTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$442.04
Offen:
$442.55
24-Stunden-Volumen:
513.08K
Relative Volume:
0.35
Marktkapitalisierung:
$111.64B
Einnahmen:
$11.74B
Nettoeinkommen (Verlust:
$3.68B
KGV:
31.02
EPS:
14.1888
Netto-Cashflow:
$3.34B
1W Leistung:
+1.62%
1M Leistung:
+7.50%
6M Leistung:
-1.34%
1J Leistung:
-7.13%
1-Tages-Spanne:
$438.61
$448.28
1-Wochen-Bereich:
$438.61
$463.85
52-Wochen-Spanne:
$362.50
$519.68
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Firmenname
Vertex Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 341-6393
Adresse
50 NORTHERN AVENUE, BOSTON, MA
Vergleichen Sie VRTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
440.03 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.09 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
416.67 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
893.79 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.57 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-09-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Eingeleitet | Raymond James | Mkt Perform |
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-19 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-04-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-02-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Herabstufung | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-05-04 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-01-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-05-06 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Bestätigt | JP Morgan | Overweight |
| 2022-01-27 | Bestätigt | Morgan Stanley | Underweight |
| 2022-01-27 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Hold |
| 2022-01-27 | Bestätigt | Wolfe Research | Outperform |
| 2022-01-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-30 | Eingeleitet | Daiwa Securities | Outperform |
| 2020-11-30 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Eingeleitet | Bernstein | Outperform |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-07-31 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-09-03 | Hochstufung | Goldman | Neutral → Buy |
| 2019-08-01 | Herabstufung | Needham | Buy → Hold |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | In-line |
| 2019-03-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten
State Street Corp Has $5.24 Billion Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by SVB Wealth LLC - MarketBeat
Daiwa Securities Group Inc. Grows Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Axa S.A. Buys 10,477 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
ASH: Beam Can Rival Vertex In Sickle Cell But Bulsufan Deaths Cast A Shadow - Citeline News & Insights
Best Biotech Stocks To Keep An Eye OnDecember 8th - MarketBeat
Disney, Nu Holdings, Phillips 66 And A Health Care Stock On CNBC's 'Final Trades' - Benzinga
Vertex Will Seek Regulatory Approval for Casgevy in Younger Sickle Cell, Beta-Thalassemia Patients - Precision Medicine Online
Why Vertex Pharmaceuticals (VRTX) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Vertex's Gene Therapy Works In Children With Blood Disorders - Benzinga
Thematics Asset Management Acquires 2,642 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions - BioSpace
David And Goliath: How A Parent-Led Buyers’ Club Challenged Cystic Fibrosis Giant Vertex - Citeline News & Insights
VRTX Stock Quote Price and Forecast - CNN
2 Stocks That Could Soar by 52% and 282%, According to Wall Street - The Motley Fool
Marshall Wace LLP Has $52.09 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
California Public Employees Retirement System Has $322.79 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Arrowstreet Capital Limited Partnership Purchases Shares of 61,470 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Down 10%, Should You Buy the Dip on Vertex Pharmaceuticals? - Nasdaq
Vertex Pharmaceuticals (NASDAQ:VRTX) Chairman Jeffrey Leiden Sells 63,781 Shares - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Charles Wagner Jr Sells 14,000 Shares - MarketBeat
Best Biotech Stocks To Watch NowDecember 6th - MarketBeat
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the - pharmiweb.com
Vertex presents new data on Casgevy at ASH - The Pharma Letter
Vertex Pharmaceuticals Incorporated Presents New Data on CASGEVY, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions - marketscreener.com
Vertex Presents New CASGEVY Data Highlighting Benefits In Children Ages 5-11 - Nasdaq
Vertex CRISPR therapy hits early goal in children with blood disorders - BioPharma Dive
Vertex's gene therapy shows promise in younger children with blood disorders - Reuters
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions - Via TT
Mirabella Financial Services LLP Reduces Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Epoch Investment Partners Inc. Sells 20,810 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
First Trust Advisors LP Purchases 143,084 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Insider Sell: WAGNER CHARLES F JR Sells 14,000 Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex Pharma executive chairman sells $28.6m in stock - Investing.com India
Vertex Pharmaceuticals Insider Sold Shares Worth $2,024,955, According to a Recent SEC Filing - marketscreener.com
VP Tatsis Sells 4,500 ($2M) Of Vertex Pharmaceuticals Inc [VRTX] - TradingView
Vertex Pharmaceuticals EVP Sells Shares Under Trading Plan - TradingView
VRTX Analyst Rating Update: Morgan Stanley Raises Price Target | VRTX Stock News - GuruFocus
Morgan Stanley Adjusts PT on Vertex Pharmaceuticals to $564 From $516, Maintains Overweight Rating - marketscreener.com
Can Vertex Pharmaceuticals Incorporated (VX1) stock sustain breakout momentumWeekly Trade Report & Technical Confirmation Trade Alerts - Newser
Why Vertex Pharmaceuticals Incorporated stock appeals to dividend seekers2025 Market Overview & Expert Curated Trade Ideas - Newser
Amundi Has $517.92 Million Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
1 Reason I'll Never Sell Vertex Pharmaceuticals Stock - Finviz
Citi Healthcare In Brief: Launch Trajectories Under Scrutiny - Citeline News & Insights
Is Vertex Pharmaceuticals Incorporated stock resilient to inflationWeekly Stock Report & Technical Confirmation Trade Alerts - Newser
Why Analysts See Vertex Pharmaceuticals Story Shifting With New Pipeline Momentum and Valuation Debates - Yahoo Finance
Harding Loevner Global Equity’s Views on Vertex Pharmaceuticals Incorporated (VRTX) - Insider Monkey
Vertex Pharmaceuticals (NASDAQ:VRTX) Raised to Overweight at Morgan Stanley - MarketBeat
Westerkirk Capital Inc. Acquires New Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals (VRTX): Assessing Valuation After Recent Multi-Month Share Price Gains - Yahoo Finance
Invesco Ltd. Raises Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Finanzdaten der Vertex Pharmaceuticals Inc-Aktie (VRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):